Matthew Parris
Chief Tech/Sci/R&D Officer bij TRAWS PHARMA, INC.
Profiel
Matthew Parris is currently working as the Vice President-Clinical Operations at Traws Pharma, Inc. He previously worked as the Director-Clinical Operations at Aegerion Pharmaceuticals, Inc. and Inovio Pharmaceuticals, Inc. He also held the position of Vice President-Clinical Development at Eleison Pharmaceuticals, Inc. Mr. Parris completed his undergraduate degree at Imperial College London.
Actieve functies van Matthew Parris
| Bedrijven | Functie | Begin |
|---|---|---|
| TRAWS PHARMA, INC. | Chief Tech/Sci/R&D Officer | 01-08-2018 |
Eerdere bekende functies van Matthew Parris
| Bedrijven | Functie | Einde |
|---|---|---|
Eleison Pharmaceuticals, Inc.
 Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | Corporate Officer/Principal | - |
| AEGERION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| INOVIO PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Opleiding van Matthew Parris
| Imperial College London | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| TRAWS PHARMA, INC. | Health Technology |
| INOVIO PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Eleison Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | Health Technology |
